Recce Pharmaceuticals Ltd
ASX:RCE.AX
0.49 (AUD) • At close September 20, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Recce Pharmaceuticals Ltd |
Symbool | RCE.AX |
Munteenheid | AUD |
Prijs | 0.495 |
Beurswaarde | 114,646,455 |
Dividendpercentage | 0% |
52-weken bereik | 0.41 - 0.695 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. James Hamilton-Bray Graham GAICD |
Website | https://www.recce.com.au |
An error occurred while fetching data.
Over Recce Pharmaceuticals Ltd
Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antiinfectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms.
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (AUD)
Cijfers zijn in miljoenen (AUD)